Close to 20,000 patients from 66 European acute care hospitals were surveyed. On the day of the survey, 7.1% had hospital associated infection or were still treated because of a hospital associated infection. 34.6% of patients were treated with at least one antimicrobial. Proportion of patients with at least one hospital associated infection was the highest in intensive care units (28.1%). Also the proportion of patients on antimicrobial therapy was the highest in intensive care units (61.4%). Pneumonia and other lower respiratory tract infections were most common hospital infections (prevalence was 2.0%) and represented 25.7% of all hospital associated infections. 17.3% of patients were on antimicrobials because of surgical prophylaxis. Of those, as many as 60.7% were receiving surgical prophylaxis for more than one day.
COBISS.SI-ID: 2852325
In this paper, we combined the clinical effect estimates from the previously published E. coli and S. aureus paper, prevalence data from EARSS and a WHO cost model to come to estimates about the number of deaths, bed days and costs associated with MRSA and G3C resistant E. coli BSI.
COBISS.SI-ID: 2554341
The objective was to estimate the excess mortality and length of hospital stay (LOS) associated with MRSA bloodstream infections (BSI) in European hospitals. Between July 2007 and June 2008, a multicenter, prospective, parallel matched-cohort study was carried out in 13 tertiary care hospitals in as many European countries. Compared to the controls, MRSA patients had higher 30-day mortality (adjusted odds ratio [aOR] =4.4) and higher hospital mortality (adjusted hazard ratio [aHR] =3.5). Their excess LOS was 9.2 days. MSSA patients also had higher 30-day (aOR =2.4) and hospital (aHR =3.1) mortality and an excess LOS of 8.6 days.
COBISS.SI-ID: 2478309
Our objectives were to determine excess mortality and length of hospital stay (LOS) attributable to bloodstream infection (BSI) caused by third-generation-cephalosporin-resistant Escherichia coli (REC) in Europe. A prospective parallel matched cohort design was used. Thirteen European tertiary care centres participated between July 2007 and June 2008. REC patients had a higher mortality at 30 days (adjusted odds ratio = 4.6) and a higher hospital mortality (adjusted hazard ratio = 5.7) than their controls. LOS was increased by 8 days. For SEC patients, these figures were adjusted odds ratio = 1.9, adjusted hazard ratio = 2.0 and excess LOS = 3 days. A 2.5 times [95% confidence interval (95% CI) 0.9–6.8] increase in all-cause mortality at 30 days and a 2.9 times (95% CI 1.2–6.9) increase in mortality during entire hospital stay as well as an excess LOS of 5 days (95% CI 0.4–10.2) could be attributed to resistance to third-generation cephalosporins in E. coli BSI.
COBISS.SI-ID: 2406117
The aim of the survey conducted by ECDC among 29 European countries (the European Union Member States, Iceland and Norway) was to gather information on the spread of NDM-1-producing Enterobacteriaceae in Europe, on public health responses and on available national guidance on detection, surveillance and control. A total of 77 cases were reported from 13 countries from 2008 to 2010. Klebsiella pneumoniae was the most frequently reported species with 54%. Among 55 cases with recorded travel history, 31 had previously travelled or been admitted to a hospital in India or Pakistan and five had been hospitalised in the Balkan region. From Slovenia two cases were reported, the first was detected in 2009 and the second in 2010. For 13 of 77 cases possible nosocomial acquisition was suspected as they have previously not travelled or been treated abroad. Enhanced surveillance of carbapenemase- producing Enterobacteriaceae in Europe and identification and implementation of effective control measures were the key highlights.
COBISS.SI-ID: 2405605